Author

Zachary F. Zimmerman

Observed names: Z Zimmerman, Z.F. Zimmerman, Zachary Zimmerman, Zimmerman, Zachary

Observed institutions: Amgen (United States), University of Miami, University of Washington, Fred Hutch Cancer Center

ORCID: 0000-0001-7948-5503

Observed ORCID: 0000-0001-7948-5503

OpenAlex ID: A5076898261

Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors

2018 · Anthony S. Stein, Gary Schiller, et al. · Annals of Hematology · 108

PDF

Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia

2019 · Hervé Dombret, Max S. Topp, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 64

PDF

2018 · Max S. Topp, Zachary Zimmerman, et al. · Blood · 50

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

2019 · Jinlin Song, Qiufei Ma, et al. · Advances in Therapy · 28

PDF

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy

2011 · Z Zimmerman, B L Scott, et al. · Bone Marrow Transplantation · 10

Treatment with Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation

2015 · Anthony Selwyn Stein, Max S. Topp, et al. · Blood · 6

Abstract 5872: CLK inhibitor BH-30236 synergizes with venetoclax in anti-leukemia activity via splicing modulation in preclinical AML and CLL models

2026 · Wei Deng, Ping Jiang, et al. · Cancer Research

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS

2025 · Eytan Stein, Alice Mims, et al. · Blood

PDF

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS

2024 · Eytan M. Stein, Leora Boussi, et al. · Blood

PDF

2019 · Xinke Zhang, Andre C. Schuh, et al. · Transplantation and Cellular Therapy

PDF

Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)

2018 · Max S. Topp, Zachary F. Zimmerman, et al. · Blood

Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

2018 · Yukio Kobayashi, Zachary F. Zimmerman, et al. · Blood

Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

2018 · Anthony S. Stein, Zachary F. Zimmerman, et al. · Blood

Allo-HSCT in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia Treated with Blinatumomab vs Standard-of-Care Chemotherapy From a Randomized Phase 3 Study

2018 · Elias Jabbour, Nicola Gökbuget, et al. · Transplantation and Cellular Therapy

Major cytotoxic pathways are required for effective resistance against hematopoietic allografts by effector cells derived from naıve but not memory recipient T cells

2005 · Z.F. Zimmerman, R.B. Levy · Transplantation and Cellular Therapy

PDF

Donor Antigen Presenting Cell CD80/86 Function Is Required for Eliciting T Cell Resistance Against Progenitor Cell Engraftment in an MHC Matched Allogeneic Non-Myeloablative Transplantation Model.

2004 · Zachary F. Zimmerman, Robert B. Levy · Blood

Both Recipient TNaive and TMemory Cells Mediate Efficient Resistance Against Marrow Allografts in the Absence of Major Cytotoxic Effector Pathways.

2004 · Zachary F. Zimmerman, Robert B. Levy · Blood

Works count: 18

Citation count: 266

H-index: 6

I10-index: 5